drugset / Trial / NCT01626664
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).
Timeline
- Start
- 2012-06
- Primary completion
- 2015-08
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 100 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 2000 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Mogamulizumab | Monoclonal antibody | 1 mg/kg | — |
| Comparator | Oxaliplatin | Small molecule | 100 mg/m2 | — |
| Comparator | Pralatrexate | Other / unclassified | 30 mg/m2 | — |